Translating Electromagnetic Signals into Non-Invasive Therapeutics
For decades, diabetes care has focused on treating symptoms, rather than addressing the core therapeutic targets. Biomolecular LLC is changing this! A functional neurophysiologic restoration for Type 2 Diabetes is possible through Non-Invasive, AI-powered electroceuticals.
Our AI-driven Neurophysiologic Electromagnetic Stimulation (nEMS) Device is the Gateway to Durable Diabetes Remission.
Neurophysiologic Electromagnetic Stimulation (nEMS) Therapy
AI-Driven Innovation for Restoring Insulin Secretion — Biomolecular LLC has developed a patented therapeutic platform that combines artificial intelligence with neurophysiologic electromagnetic stimulation (nEMS) to restore pancreatic β-cell function. This non-invasive approach offers a transformative alternative to traditional drug-based diabetes treatments.
How It Works
Our nEMS therapy uses targeted electromagnetic pulses to stimulate neurophysiologic pathways that regulate pancreatic function. AI algorithms personalize stimulation protocols based on patient-specific data, optimizing therapeutic outcomes and minimizing side effects.
Scientific Foundation
Our technology is built on decades of research in electrophysiology, biomedical engineering, and artificial intelligence. Inspired by pioneers like Luigi Galvani and Robert Bárány, we apply classical bioelectric principles to modern therapeutic design.
- Electrophysiologic modulation of β-cell activity
- Machine learning for adaptive therapy control
- Bioelectronic device engineering and sensor integration
Key Features
- Non-invasive and drug-free
- AI-guided treatment personalization
- Restores natural insulin secretion
- Targets both Type 1 and Type 2 diabetes mechanisms
Development Status
- Market-ready prototype completed
- Preclinical validation underway
- Seeking federal funding for clinical trials and regulatory approval
- Aligned with NIH, NSF, and DoD research priorities
How nEMS Therapy Works
Pathway adapted from U.S. Patent No. 8,457,745 – Method for Pancreatic β-cell Control
A market-ready prototype.
Preclinical validation underway.
BASED ON PARADIGM-SHIFTING PRE-CLINICAL DATA
Pre-clinical research led by our Founder and Principal Investigator, Dr. Oresteban Carabeo, demonstrated durable therapeutic effects in T2DM patients. Three ethnic groups discontinued insulin therapy within five months of our nEMS therapy trial, with therapeutic durability lasting throughout the year. This is the first peripheral therapy to achieve a promising and durable remission for T2DM.
Data adapted from U.S. Patent No. 8,457,745 – Method for Pancreatic β-cell Control
THE GLOBAL DIABETES CRISIS & HUMAN IMPACT
Global cost of diabetes is set to double by 2030. The International Diabetes Federation (IDF) projects a substantial cost of $2.1 trillion. This translates to a significant portion of the world's economic output. The study found that the costs of diabetes as a share of global GDP are expected to rise from 1.8% in 2015 to a high of 2.2% by 2030 (Bommer et al., 2018).
This highlights the urgent need for policymakers to take decisive action to address the growing burden of diabetes on individuals, healthcare systems, and economies worldwide. Innovative, durable therapeutic solutions — like nEMS therapy — are essential to reversing this trajectory.
Find out more
mission statement
Biomolecular LLC is an independent R&D organization pioneering AI-driven nEMS therapy with a mission to advance bioelectronic medicine in diabetes care and eliminate dependence on lifelong medication.
Get in Touch
Biomolecular LLC
Translating Electromagnetic Signals into Non-Invasive Therapeutics
Oresteban Carabeo, PhD
Founder, CEO & Principal Investigator
15630 Northwest 37th Avenue, Miami Gardens, FL, USA
Office: (980) 833-8951
Email: [email protected]
Hours: Mon–Fri 09:00 am – 05:00 pm | Sat–Sun Closed